Vir Biotechnology (VIR) Net Margin (2018 - 2026)
Vir Biotechnology (VIR) posted Net Margin of 433431.03% for Q1 2026, down 646870.77% sequentially from 66.99% in Q4 2025, and down 42944142.0% YoY from N/an in Q1 2025.
Vir Biotechnology (VIR) Net Margin (2018 - 2026) Analysis & Trends
Vir Biotechnology has reported Net Margin for 9 years, with the latest figure at 433431.03% in Q1 2026.
- Quarterly Net Margin fell 42944142.0% year-over-year to 433431.03% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 675.36% (up 209368.0% YoY) and the FY2025 annual result came in at 638.87%, up 6453.0% from the prior year.
- Net Margin slipped to 433431.03% in Q1 2026 per VIR's latest filing, from 66.99% in the prior quarter.
- Over five years, Net Margin peaked at 46.81% in Q3 2022 and troughed at 433431.03% in Q1 2026.
- A 5-year average of 31858.58% and a median of 845.23% in 2024 frame the typical range for Net Margin.
- The sharpest annual moves came in 2022 and 2026: Net Margin soared 859021 bps in 2022, then tumbled 42944142 bps in 2026.
- Over 5 years, Net Margin stood at 205.63% in 2022, then plunged by 236 bps to 690.85% in 2023, then retreated by 22 bps to 845.23% in 2024, then soared by 92 bps to 66.99% in 2025, then tumbled by 646871 bps to 433431.03% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 433431.03%, 66.99%, and 67975.42% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Vir Biotechnology | 1.56 Bn | 1.56 Bn | 238.95 Mn | 33.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.51% |
| Mar 31, 2026 | -433,431.03% |
| Dec 31, 2025 | -66.99% |
| Sep 30, 2025 | -67,975.42% |
| Jun 30, 2025 | -9,139.87% |
| Mar 31, 2025 | -3,989.61% |
| Dec 31, 2024 | -845.23% |
| Sep 30, 2024 | -8,979.71% |
| Jun 30, 2024 | -4,500.10% |
| Mar 31, 2024 | -126.26% |
| Dec 31, 2023 | -690.85% |
| Sep 30, 2023 | -6,192.23% |
| Jun 30, 2023 | -5,129.71% |
| Mar 31, 2023 | -223.80% |
| Dec 31, 2022 | -205.63% |
| Sep 30, 2022 | 46.81% |
| Jun 30, 2022 | -188.27% |
| Mar 31, 2022 | 42.08% |
| Dec 31, 2021 | 64.63% |
| Sep 30, 2021 | 106.57% |